Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.1342
- Book/Share 32.4693
- PB 4.7981
- Debt/Equity 0.669
- CurrentRatio 1.2574
- ROIC 0.1201
- MktCap 374841645300.0
- FreeCF/Share 7.7211
- PFCF 20.181
- PE 17.1835
- Debt/Assets 0.2698
- DivYield 0.0322
- ROE 0.2995
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
I Have Invested in Dividends For 15 Years—These Dividend Aristocrats Built My Passive Income Stream
Published: July 09, 2025 by: 24/7 Wall Street
Sentiment: Positive
These dividend aristocrats haven't disappointed me in 15 years and won't disappoint you either.
Read More
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
Read More
Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?
Published: July 09, 2025 by: Seeking Alpha
Sentiment: Positive
JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on the 16th ofJuly. JNJ has a long history of beating consensus EPS estimates by 5.5% on average. The Q2 sales growth could potentially be the weakest of the 4 quarters of the year.
Read More
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Published: July 08, 2025 by: CNBC
Sentiment: Neutral
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Dogs of the Dow: These Are The Best Dividend Stocks in July 2025
Published: July 08, 2025 by: 24/7 Wall Street
Sentiment: Positive
If you're keen on following the Dogs of the Dow investing strategy, here are three stocks with a high-yield.
Read More
3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend
Published: July 07, 2025 by: 24/7 Wall Street
Sentiment: Positive
The vast majority of investors don't have hundreds of thousands to bet on each stock.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Negative
JNJ's MedTech unit eyes second-half growth despite China headwinds, U.S. competition and tariff pressure.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
2 Bulletproof Dividend Stocks to Buy in July
Published: July 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
While a high dividend yield is attractive, the consistency makes a stock worth holding.
Read More
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Johnson & Johnson (JNJ) Could Be a Great Choice
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.
Read More
Johnson & Johnson: Patience Will Be Rewarded
Published: June 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson faces legal pressures from talc lawsuits, which is likely to create persisting growth and valuation headwinds. The latest dividend increase of 4.8% signals continued profit growth, though below JNJ's historical average. However, I believe the market has also priced in these issues already.
Read More
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.
Read More
Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson is a stable, dividend-growth powerhouse with 62 years of increases and a 3.44% forward yield, ideal for conservative, long-term investors. Despite recent legal headwinds and flat core growth, JNJ remains undervalued, trading at a significant discount to the sector median P/E. Talc litigation overhang has depressed sentiment, but 95% of cases are resolved and market recovery suggests the worst is priced in.
Read More
How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Income Accelerator Portfolio balances income, growth, and capital appreciation, now enhanced by the global diversification from Allianz and LVMH. We focus on financially healthy companies with sustainable dividends and strong competitive advantages, optimizing risk-reward through sector and geographic diversification. The portfolio's Weighted Average Dividend Yield [FWD] of 4.05% and 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.06% project a Yield on Cost above 11% in 15 years.
Read More
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Negative
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
Read More
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
Read More
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG IMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year for the broadest population of individuals living with gMG, including anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older SPRING HOUSE, Pa. , June 23, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ …
Read More
If I Could Only Buy 2 Dividend Stocks: June's Top Picks For Global Diversification
Published: June 20, 2025 by: Seeking Alpha
Sentiment: Positive
I added Allianz and LVMH to The Dividend Income Accelerator Portfolio for their blend of dividend yield, growth, and financial strength. Both companies offer strong dividend growth potential—Allianz with a Dividend Yield [FWD] of 4.31%, and LVMH with a Dividend Yield [FWD] of 3.19%—plus robust long-term growth prospects. These additions improve our portfolio's potential risk-adjusted returns, valuation, and global diversification, aligning with our strategy of balancing income and growth.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Smart Moves With $5,000: Dividend Stocks to Own Amid Market Chaos
Published: June 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Allocating 10% to 20% to dividend stocks balances growth-heavy portfolios, leveraging compounding returns to navigate geopolitical and monetary challenges.
Read More
Johnson & Johnson CEO: “We're in the Golden Era of Medical Innovation”
Published: June 17, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Johnson & Johnson Chairman and CEO Joaquin Duato believes that we are now in a “golden era” of innovation, particularly in the United States. Venture capital plays a vital early-stage role, but big pharma provides the infrastructure and market access.
Read More
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
Read More
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose MILAN , June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell …
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100